ASCO 2021: Pembrolizumab as adjuvant therapy for kidney cancer

Adjuvant therapy is medication that is given in addition to surgery (nephrectomy) to try to prevent the cancer from coming back. Adjuvant therapy can be used to kill any remaining microscopic cancer cells, or it can control the growth of any remaining cancer. Nephrectomy is the standard of care for renal cell carcinoma (RCC); however, […]

read more

Adjuvant pembrolizumab extends disease-free survival in kidney cancer patients

Interim results from a phase 3 clinical trial called KEYNOTE-564 have shown that pembrolizumab given after nephrectomy (adjuvant pembrolizumab) for intermediate to high risk renal cell carcinoma (RCC) prolonged disease-free survival compared with placebo. Adjuvant pembrolizumab also improved disease-free survival in patients who had surgery to remove metastases. The study included 950 patients with renal […]

read more

IKCS 2020: Treatment selection in kidney cancer

During this interview, Dr Rana McKay from the University of California in San Diego gives a succinct overview of the 19th Annual Meeting of the International Kidney Cancer Symposium (IKCS 2020), including highlights from the meeting. She also discussed the effects of delaying surgery for patients with low stage (T1 and T2) renal cell carcinoma […]

read more

Stereotactic radiation for the treatment of kidney cancer

This paper reviews the use of stereotactic body radiotherapy (SBRT) for the treatment of renal cell carcinoma (RCC), and was presented at the Society of Urologic Oncology (SUO) in Washington last week. In conclusion: RCC is radiosensitive and SBRT can be used to stabilise or manage the symptoms of primary tumours SBRT may be useful […]

read more

ESMO 2019: Results from SORCE clinical trial with adjuvant sorafenib

Results from the SORCE clinical trial to assess sorfenib as an adjuvant treatment for renal cell carcinoma (RCC) at intermediate or high risk of relapse were presented at the European Society for Medical Oncology (ESMO) conference in Barcelona over the weekend. As for previous large randomised phase 3 clinical trials (ASSURE, PROTECT, and ATLAS) to […]

read more

ASCO 2019: Effectiveness of pazopanib after kidney cancer metastasectomy

In this phase III study, presented at the American Society of Clinical Oncology (ASCO) 2019 annual meeting in Chicago this week, the use of treatment with pazopanib after surgery to remove renal cell carcinoma (RCC) metastases (metastasectomy) was investigated. One hundred and twenty-nine patients with no evidence of disease after surgery to remove RCC metastases […]

read more

A review of adjuvant therapy options for kidney cancer

In this paper, published in Current Treatment Options in Oncology last month, the authors review the recent randomised controlled clinical trials looking at the use of post-surgery (adjuvant) vascular endothelial growth factor (VEGF) inhibitors for the treatment of renal cell carcinoma (RCC) that has not spread. The authors recommend, based on current data, that adjuvant […]

read more

Lymph node dissection identifies patients at high risk of kidney cancer spread

A recent study published in the journal Science Direct suggests that lymph node dissection (lymphadenectomy) in patients with non-metastatic renal cell carcinoma (RCC) at high risk of recurrence/spread could be used to identify patients who are most likely to benefit from adjuvant therapy. In the study, the researchers retrospectively assessed the progression of the disease in […]

read more

ESOU 2019: Adjuvant therapy after nephrectomy for high-risk renal cell carcinoma

The following presentations were given at the European Association of Urology (EAU) Section of Oncological Urology (ESOU) conference in Prague, Czech Republic last week. The first presentation approached the discussion of adjuvant therapy after nephrectomy for high-risk renal cell carcinoma (RCC) from a urologist’s perspective, while the second presentation presents the oncologist’s perspective. Read the urologist’s perspective […]

read more

MD Anderson Cancer Center 13th Update on the Management of Genitourinary Malignancies Conference

The MD Anderson Cancer Center (MDACC) 13th Update on the Management of Genitourinary Malignancies Conference took place in Houston, Texas at the end of last week (9-10 November). Kidney cancer highlights from the meeting have been published by UroToday. You can read more online on UroToday below: MDACC 2018: Promising Emerging Systemic Therapies for mRCC MDACC […]

read more
Showing 1 to 10 of 35 results
  TOP